Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 86% (32/37) CRC AND 73% (27/37) CR IN NEWLY DIAGNOSED NPM1-M AML, WITH 68% (17/25) OF CRC RESPONDERS ACHIEVING MOLECULAR MRD NEGATIVITY BY CENTRAL NGS  MEDIAN DURATION OF COMPLETE RESPONSE AND OVERALL SURVIVAL NOT YET REACHED IN NEWLY DIAGNOSED NPM1-M PATIENTS AS OF DATA CUTOFF   65% (31/48) ORR IN R/R NPM1-M AML, 83% (19/23) ORR IN VENETOCLAX-NAVE   41% (13/32) ORR IN R/R KMT2A-R AML, 70% (7/10) ORR IN VENETOCLAX-NAVE   TRIPLET COMBINATION WAS WELL TOLERATED IN BOTH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY SETTINGS; ADDITION OF ZIFTOMENIB DID NOT INCREASE TOXICITY BEYOND THAT EXPECTED WITH VENETOCLAX/AZACITIDINE ALONE   ZIFTOMENIB'S BROAD CLINICAL DEVELOPMENT PROGRAM SPANS MULTIPLE FRONT-LINE AND RELAPSED/REFRACTORY REGIMENS ACROSS NPM1-M, FLT3-M AND KMT2A-R AML SUBTYPES   COMPANY-SPONSORED REGISTRATIONAL TRIALS OF ZIFTOMENIB IN FRONT-LINE AML ARE ONGOING IN BOTH INTENSIVE CHEMOTHERAPY-ELIGIBLE AND -INELIGIBLE PATIENTS   KURA ONCOLOGY TO HOST A VIRTUAL INVESTOR EVENT TODAY, DECEMBER 8, 2025, AT 12:30 P.M. ET / 9:30 A.M.

KURA ONCOLOGY AND KYOWA KIRIN REPORT COMBINATION DATA FOR KOMZIFTI (ZIFTOMENIB) WITH VENETOCLAX AND AZACITIDINE IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY AML

SAN DIEGO, DEC. 03, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT IT WILL BE HOSTING A VIRTUAL ANALYST AND INVESTOR EVENT ON MONDAY, DECEMBER 8, 2025, AT 12:30 PM ET / 9:30 AM PT, TO DISCUSS DATA ON THE TRIPLET COMBINATION OF ZIFTOMENIB (KOMZIFTI) WITH VENETOCLAX AND AZACITIDINE IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA SCHEDULED FOR PRESENTATION AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING. THE VIRTUAL EVENT WILL FEATURE MEMBERS OF THE MANAGEMENT TEAM ALONGSIDE LEAD INVESTIGATORS.

KURA ONCOLOGY TO HOST VIRTUAL INVESTOR EVENT TO DISCUSS DATA PRESENTED AT ASH 2025 ON TRIPLET COMBINATION OF ZIFTOMENIB (KOMZIFTI) WITH VENETOCLAX AND AZACITIDINE IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

SAN DIEGO, DEC. 02, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC.(NASDAQ: KURA, KURA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THE FIRST U.S. COMMERCIAL SALE OF KOMZIFTI (ZIFTOMENIB) HAS BEEN COMPLETED. UNDER KURA'S COLLABORATION AND LICENSE AGREEMENT WITH KYOWA KIRIN CO. LTD. AND KYOWA KIRIN, INC. (COLLECTIVELY, KYOWA KIRIN), THIS MILESTONE TRIGGERS A $135 MILLION PAYMENT FROM KYOWA KIRIN TO KURA, WHICH KURA EXPECTS TO RECEIVE PRIOR TO YEAR-END. KOMZIFTI WAS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION ON NOVEMBER 13, 2025.

FIRST U.S. COMMERCIAL SALE OF KOMZIFTI TRIGGERS $135 MILLION MILESTONE PAYMENT TO KURA ONCOLOGY UNDER COLLABORATION AND LICENSE AGREEMENT WITH KYOWA KIRIN

KOMZIFTI, THE FIRST AND ONLY ONCE-DAILY FDA-APPROVED MENIN INHIBITOR FOR R/R NPM1-MUTATED AML, IS NOW COMMERCIALLY AVAILABLE IN THE UNITED STATES KOMZIFTI, THE FIRST AND ONLY ONCE-DAILY FDA-APPROVED MENIN INHIBITOR FOR R/R NPM1-MUTATED AML, IS NOW COMMERCIALLY AVAILABLE IN THE UNITED STATES

KOMZIFTI (ZIFTOMENIB) ADDED TO NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES FOR ACUTE MYELOID LEUKEMIA (AML)

 NPM1 MUTATIONS, ONE OF THE MOST COMMON GENETIC DRIVERS OF AML, ARE NOW ACTIONABLE FOR PATIENTS   ACUTE UNMET NEED IN R/R NPM1-MUTATED AML DEFINED BY HISTORICALLY POOR OUTCOMES AND LOW SURVIVAL RATES AT RELAPSE   FDA GRANTS FULL APPROVAL OF KOMZIFTI AHEAD OF PDUFA TARGET ACTION DATE   APPROVAL IS BASED ON THE KOMET-001 TRIAL, IN WHICH KOMZIFTI DEMONSTRATED DEEP RESPONSES, A POTENTIALLY BEST-IN-CLASS SAFETY PROFILE, ONCE-DAILY ADMINISTRATION, AND EASE OF CO-ADMINISTRATION WITH COMMON SUPPORTIVE MEDICATIONS IN ADULT PATIENTS WITH R/R NPM1-MUTATED AML   KOMZIFTI APPROVAL GRANTED WITH NO BOXED WARNING RELATED TO QTC PROLONGATION OR TORSADES DE POINTES   KURA ONCOLOGY WILL HOST A CONFERENCE CALL ON NOVEMBER 13, 2025, AT 12:30 PM ET / 9:30 AM PT SAN DIEGO AND TOYKO, NOV. 13, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA) AND KYOWA KIRIN CO., LTD. (TSE: 4151) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FULL APPROVAL OF KOMZIFTI(ZIFTOMENIB) FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE NPM1 MUTATION WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS.

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FDA APPROVAL OF KOMZIFTI (ZIFTOMENIB), THE FIRST AND ONLY ONCE-DAILY TARGETED THERAPY FOR ADULTS WITH RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA

SAN DIEGO, NOV. 12, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCE:

KURA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

SAN DIEGO, NOV. 07, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON NOVEMBER 3, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 21,750 SHARES OF COMMON STOCK TO A NEW NON-EXECUTIVE EMPLOYEE UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEE'S EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

 NEW DRUG APPLICATION FOR ZIFTOMENIB IN ADULTS WITH R/R NPM1-M AML REMAINS UNDER FDA PRIORITY REVIEW, WITH A PDUFA TARGET ACTION DATE OF NOVEMBER 30, 2025 

KURA ONCOLOGY REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

 MILESTONE TRIGGERED BY DOSING OF FIRST PATIENT IN THE SECOND OF TWO FRONTLINE AML PHASE 3 CLINICAL TRIALS   MILESTONE TRIGGERED BY DOSING OF FIRST PATIENT IN THE SECOND OF TWO FRONTLINE AML PHASE 3 CLINICAL TRIALS 

KURA ONCOLOGY RECEIVES SECOND $30 MILLION DEVELOPMENT MILESTONE PAYMENT IN AML MENIN INHIBITOR PROGRAM WITH KYOWA KIRIN

 DATA TO BE FEATURED IN TWO ORAL PRESENTATIONS ON DECEMBER 8, 2025   BROAD DEVELOPMENT PROGRAM ASSESSES ZIFTOMENIB ACROSS DIVERSE AML SEGMENTS AND TREATMENT PARADIGMS TO INFORM APPROPRIATE USE  SAN DIEGOANDTOKYO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC.(NASDAQ: KURA, KURA) ANDKYOWA KIRIN CO., LTD.(TSE: 4151, KYOWA KIRIN) TODAY ANNOUNCED THAT RESULTS FROM THE KOMET-007 COMBINATION TRIAL OF ZIFTOMENIB, A ONCE-DAILY, ORAL INVESTIGATIONAL MENIN INHIBITOR, WILL BE FEATURED IN TWO ORAL PRESENTATIONS AT THE UPCOMING AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2025 ANNUAL MEETING, ON DECEMBER 8, 2025 IN ORLANDO, FL.

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE PRESENTATIONS OF ZIFTOMENIB VEN/AZA COMBINATION DATA IN FRONTLINE AND RELAPSED/REFRACTORYNPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA AT 2025 ASH ANNUAL MEETING

Kura Oncology, Inc.

KURA

Price

Financial Reports

No items found.

Press Releases

Kura Oncology, Inc.

KURA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

KURA